Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
See our latest analysis for Beam Therapeutics. The recent FDA alignment on BEAM-302 and the extended cash runway appear to be in focus for traders, with a 1-day share price return of 22.29% pushing Beam to US$33.69 and contributing to a 24.13% year to date share price return. This sits alongside a 1-year total shareholder return of 44.59%, which contrasts with a 3-year total shareholder return decline of 24.21% and a 5-year total shareholder return decline of 69.06%, suggesting short term momentum is picking up against a weaker longer term record. If this kind of biotech catalyst has caught your eye, it could be a good moment to scan other healthcare stocks that are moving on clinical or regulatory updates as well. With shares now at US$33.69, a 34% gap to the average analyst price target and a long history of volatility, you have to ask yourself: is Beam still trading below its potential, or is the market already pricing in future growth? According to davidlsander, the narra
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial TransitionGlobeNewswire
- Beam Therapeutics (NASDAQ:BEAM) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BEAM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at UBS Group AG to a "hold" rating.MarketBeat
BEAM
Earnings
- 11/4/25 - Miss
BEAM
Sec Filings
- 1/12/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- BEAM's page on the SEC website